

Christoph RÄŕllig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4210882/publications.pdf>

Version: 2024-02-01

98
papers

7,407
citations

109137

35
h-index

58464

82
g-index

105
all docs

105
docs citations

105
times ranked

7418
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> , 2022, 139, 87-103.	0.6	82
2	Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. <i>Leukemia</i> , 2022, 36, 111-118.	3.3	31
3	Differential impact of <i>IDH1</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	2.5	17
4	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922.	3.3	23
5	Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse. <i>Cancer Management and Research</i> , 2022, Volume 14, 547-559.	0.9	0
6	Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. <i>BMC Cancer</i> , 2022, 22, 201.	1.1	14
7	Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. <i>Blood Advances</i> , 2022, 6, 3294-3303.	2.5	11
8	Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD. <i>Frontiers in Oncology</i> , 2022, 12, 862991.	1.3	1
9	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. <i>Blood Advances</i> , 2022, , .	2.5	13
10	Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. <i>Blood Advances</i> , 2022, 6, 3684-3696.	2.5	5
11	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	6.9	17
12	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	23
13	Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 2208-2217.	3.3	8
14	A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	4
15	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	0.6	805
16	miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 1933-1948.	3.3	22
17	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranilcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021, 35, 701-711.	3.3	56
18	Treatment of Newly Diagnosed AML in Fit Patients. <i>Hematologic Malignancies</i> , 2021, , 199-213.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> , 2021, 35, 2517-2525.	3.3	40
20	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 2095.	1.7	7
21	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. <i>Haematologica</i> , 2021, 106, 3100-3106.	1.7	14
22	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. <i>Blood</i> , 2021, 138, 507-519.	0.6	40
23	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 3279-3289.	2.5	21
24	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 164.	2.8	29
25	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	5.8	17
26	The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5584-5587.	2.5	8
27	Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. <i>Trials</i> , 2021, 22, 765.	0.7	2
28	A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse. <i>Blood</i> , 2021, 138, 2345-2345.	0.6	3
29	Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 776946.	1.3	1
30	Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 691-697.	2.0	8
31	The clinical mutator of core binding factor leukemia. <i>Leukemia</i> , 2020, 34, 1553-1562.	3.3	60
32	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i> Internal Tandem Duplication Mutation (SORMAIN). <i>Journal of Clinical Oncology</i> , 2020, 38, 2993-3002.	0.8	335
33	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e228-e231.	1.7	29
34	The prevalence of extramedullary acute myeloid leukemia detected by ¹⁸ F-FDG-PET/CT: final results from the prospective PETAML trial. <i>Haematologica</i> , 2020, 105, 1552-1558.	1.7	31
35	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020, 136, 823-830.	0.6	85
36	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 807-815.	1.1	53

#	ARTICLE	IF	CITATIONS
37	Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia. Biomarker Research, 2020, 8, 20.	2.8	7
38	Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia. Annals of Hematology, 2020, 99, 2173-2180.	0.8	12
39	MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1â€“2a trial. Lancet Haematology, the, 2020, 7, e381-e394.	2.2	59
40	Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. Leukemia Research, 2019, 85, 106192.	0.4	9
41	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research, 2019, 85, 106197.	0.4	16
42	Oral targeted agent versus chemotherapy in acute myeloid leukaemia. Lancet Oncology, The, 2019, 20, 896-898.	5.1	0
43	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	5.1	254
44	Characterization of acute myeloid leukemia with del(9q) â€“ Impact of the genes in the minimally deleted region. Leukemia Research, 2019, 76, 15-23.	0.4	16
45	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	6.3	187
46	Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2019, 134, 13-13.	0.6	16
47	Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Annals of Oncology, 2018, 29, 973-978.	0.6	27
48	Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin. PLoS ONE, 2018, 13, e0204290.	1.1	15
49	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 1668-1679.	5.1	250
50	PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia. Blood, 2018, 132, 1472-1472.	0.6	2
51	Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemiaâ€“Lessons Learned from the Prospective BRIDGE Trial. Biology of Blood and Marrow Transplantation, 2017, 23, 1491-1497.	2.0	12
52	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1â€“2 study. Lancet Oncology, The, 2017, 18, 1061-1075.	5.1	402
53	Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 889-896.e5.	0.2	4
54	Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Cancer Management and Research, 2017, Volume 9, 97-102.	0.9	50

#	ARTICLE	IF	CITATIONS
55	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. <i>Blood</i> , 2017, 130, 721-721.	0.6	20
56	Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome. <i>Stem Cells</i> , 2016, 34, 357-366.	1.4	80
57	<i>TP53</i> mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 172, 914-922.	1.2	74
58	A high BMI is a risk factor in younger patients with <i>de novo</i> acute myelogenous leukemia. <i>European Journal of Haematology</i> , 2016, 97, 17-24.	1.1	21
59	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1988-1996.	2.0	40
60	Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 462-469.	2.0	74
61	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2016, 128, 1069-1069.	0.6	35
62	A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 1152-1152.	0.6	35
63	MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study. <i>Journal of Clinical Oncology</i> , 2016, 34, 8012-8012.	0.8	12
64	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	13.9	1,139
65	Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial. <i>Annals of Hematology</i> , 2015, 94, 557-563.	0.8	7
66	How I treat hyperleukocytosis in acute myeloid leukemia. <i>Blood</i> , 2015, 125, 3246-3252.	0.6	155
67	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	5.1	347
68	Multiple myeloma. <i>Lancet</i> , The, 2015, 385, 2197-2208.	6.3	511
69	Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 3035-3035.	0.6	8
70	Mutations of cMYC Exon 2 Are a Rare but Recurrent Abnormality in Adult Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 1408-1408.	0.6	0
71	Outcome of patients with abn(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 123, 2960-2967.	0.6	62
72	Clonal Hematopoiesis in AML Patients in Hematological CR Is Present in Many Patients with Intermediate Risk AML and Is Associated with a High Prevalence of DNMT3A gene Mutations. <i>Blood</i> , 2014, 124, 121-121.	0.6	9

#	ARTICLE	IF	CITATIONS
73	The Prevalence of Extramedullary AML Detected By 18-FDG/PET-CT: Results from the Prospective PET-AML Trial. <i>Blood</i> , 2014, 124, 2270-2270.	0.6	7
74	Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soramf Trial. <i>Blood</i> , 2014, 124, 6-6.	0.6	34
75	Targeted Resequencing of MLL-PTD Positive AML Patients Reveals a High Prevalence of Co-Occurring Mutations in Epigenetic Regulator Genes. <i>Blood</i> , 2014, 124, 1035-1035.	0.6	0
76	Reconstitution of Interleukin-17-Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 357-365.	2.0	11
77	High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2094-2102.	0.8	71
78	The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. <i>Blood</i> , 2013, 122, 83-92.	0.6	169
79	Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis. <i>Blood</i> , 2013, 122, 489-489.	0.6	1
80	TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 711-711.	0.6	0
81	Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag. <i>Blood</i> , 2013, 122, 4923-4923.	0.6	0
82	Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML - Results Of The Bridge Trial -. <i>Blood</i> , 2013, 122, 304-304.	0.6	0
83	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1062-1067.	0.6	23
84	Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2012, 93, 744-749.	0.5	47
85	Reconstitution of 6-Sulfo LacNAc Dendritic Cells After Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2012, 93, 1270-1275.	0.5	5
86	Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. <i>Lancet Oncology</i> , 2012, 13, 207-214.	5.1	69
87	Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia - A Randomised SAL Pilot Study. <i>PLoS ONE</i> , 2012, 7, e52695.	1.1	25
88	Induction of Cellular Immune Responses in Patients With Stage-I Multiple Myeloma After Vaccination With Autologous Idiotype-pulsed Dendritic Cells. <i>Journal of Immunotherapy</i> , 2011, 34, 100-106.	1.2	47
89	18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1552-1556.	1.7	104
90	Cytarabine Dose of 36 g/m ² Compared With 12 g/m ² Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2696-2702.	0.8	94

#	ARTICLE	IF	CITATIONS
91	Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System. <i>Journal of Clinical Oncology</i> , 2011, 29, 2758-2765.	0.8	220
92	A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. <i>Blood</i> , 2010, 116, 971-978.	0.6	157
93	Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. <i>Lancet, The</i> , 2010, 376, 2000-2008.	6.3	290
94	The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review. <i>Cancer Treatment Reviews</i> , 2009, 35, 425-430.	3.4	35
95	Chlorpromazine Combined with Cidofovir for Treatment of a Patient Suffering from Progressive Multifocal Leukoencephalopathy. <i>Intervirology</i> , 2007, 50, 412-417.	1.2	20
96	Arsenic-induced APL differentiation in cerebrospinal fluid. <i>Leukemia Research</i> , 2007, 31, 703-705.	0.4	21
97	Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 268-276.	2.0	63
98	Akute myeloische Leukämie: Therapie im Wandel. , 0, , .		1